
LITU alumnus Kirti Ganorkar is Sun Pharma's MD
2
3
Nagpur: Kirti Ganorkar, an alumnus of LIT University's batch of 1988, has been appointed as the managing director of Sun Pharmaceutical Industries Ltd.
Ganorkar joined Sun Pharma in 1996 and has held various leadership roles across business development, marketing, M&A, new product introduction, project management, IP and litigation.
He has played a pivotal role in driving Sun Pharma's foray into specialty by securing rights for key products such as Ilumya.
Ganorkar led Sun Pharma's entry into Japan and laid initial groundwork for the company's Europe entry. He has impactfully led Sun Pharmaceutical's US business with stewardship of several notable generic programmes from concept to commercialisation. He has been heading the India Business at Sun Pharmaceuticals since June 2019.
Under his leadership, Sun Pharma's India Business has grown consistently, further increasing its market share.
Laxminarayan Innovation Technological University, since its inception as LIT in 1942, has given the global industry several towering stalwarts. The year 2025 has been a momentous one for LIT University alumni. Earlier this year, Subramanian Sarma, an LIT University alumnus of 1979 batch of chemical engineering was appointed as the deputy managing director of Larsen & Toubro (L&T). Each year, LIT University reinforces its position as one of the most premier institutes in chemical engineering and technology by producing such stalwarts.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
2 hours ago
- Time of India
Maker of GLP1 pens scales up for generic debuts
As weight-loss drug sales surge with semaglutide's patent expiration, Gujarat's Shaily Engineering Plastics, an injector pen manufacturer, anticipates significant growth. Its stock has nearly doubled, and the company is doubling its production capacity to 80-85 million pens by fiscal year-end to meet rising domestic and export demands. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: With sales of weight-loss drugs surging and set to go up even more as semaglutide goes off patent early next year, a low-profile manufacturer of injector pens, Gujarat-based Shaily Engineering Plastics , is set to reap a windfall. Its stock has nearly doubled over the past 12 months. Manufacturers of the pen-like devices that make it easy to self-administer metered doses that would otherwise need to be injected with a syringe are the unnoticed beneficiaries of weight-loss drugs becoming is doubling capacity in line with plans of top pharma companies to launch generic versions of GLP1 weight-loss drugs early next year in India and overseas, said a senior company executive. It will be increasing capacity to 80-85 million pens by this fiscal year end from 40-45 million currently to cater to domestic and export demand, Sanjay Shah, chief strategy officer, told ET."We will look at further expansion and ramp up (in FY27). Currently, we are working with multiple players who are looking to launch generic semaglutide in different markets," he to Shah, various estimates suggest global demand for injector pens is likely to reach 500 million per year in the next two-three years and about 2 billion by is leading industry insiders to predict a looming supply crunch for pen leading drugmakers like Sun Pharma , Dr Reddy's, Cipla and Lupin are expected to be a part of the first-day launch wave in several international markets and India as soon as the patent is investing about '125 crore in FY26 on capacity expansion of its IP-led pen platform."We will be expanding (capacity) going forward to cater to the global as well as domestic market," said drugmaker Novo Nordisk 's weight-loss molecule semaglutide, branded Ozempic and Wegovy , will go off patent in March next year, opening up the gates for Indian and overseas drugmakers to launch cheaper generic expect an immediate price reduction of 50% and further by 60-80% over the coming years. This will boost affordability, potentially spurring sales of the drug and consequently, injector the past, shortages of both Eli Lilly's tirzepatide and Novo's semaglutide in the US were largely due to lack of devices and fill-n-finish capacities after demand for the drugs far outstripped supply.


Time of India
8 hours ago
- Time of India
Sugandha Sharma joins Publicis Global Delivery as SVP
CHRO Club #ChangeMaker: Suresh Rai, Sun Pharma | S2 E8 CEO Chronicles Uncovering the people agenda of the C-Suite WhatsApp Channel Tune in to know the latest updates on the HR community


Time of India
8 hours ago
- Time of India
Wipro promotes Dennis Sehgal to HR Director
CHRO Club #ChangeMaker: Suresh Rai, Sun Pharma | S2 E8 CEO Chronicles Uncovering the people agenda of the C-Suite WhatsApp Channel Tune in to know the latest updates on the HR community